StreetInsider.com News Articles

Form 144 Alamar Biosciences, Inc. Filed by: Qiming Venture Partners VIII-HC, L.P.

Wed, 14 Oct 2026 20:33:00 -0400

si-local-file:///var/storage/secattach/20261014/27188223.html

Form 144 Alamar Biosciences, Inc. Filed by: Qiming Venture Partners VIII Investments, LLC

Wed, 14 Oct 2026 20:23:00 -0400

si-local-file:///var/storage/secattach/20261014/27188214.html

Form 144 Alamar Biosciences, Inc. Filed by: Qiming Venture Partners VI, L.P.

Wed, 14 Oct 2026 20:21:00 -0400

si-local-file:///var/storage/secattach/20261014/27188212.html

Form 144 Alamar Biosciences, Inc. Filed by: Qiming Managing Directors Fund VI, L.P.

Wed, 14 Oct 2026 20:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27188207.html

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Thu, 08 Oct 2026 16:05:00 -0400

FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on Tuesday, November 3, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Thu, 08 Oct 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.

Alamar Biosciences adds former Grail CEO to board, expands team

Mon, 05 Oct 2026 16:05:24 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced the appointment of Bob Ragusa to its board of directors, along with two additions to its executive leadership team.

Ragusa most recently served as chief executive officer of Grail, a multi-cancer early detection company, and previously as chief operating officer of Illumina. He brings more than two decades of experience in genomics, diagnostics, and biotech.

"I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time," Ragusa said in the statement.

Alamar also named John Brottem as general counsel. Brottem previously served as general

Alamar Biosciences adds former Grail CEO to board, expands team

Mon, 05 Oct 2026 16:05:24 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced the appointment of Bob Ragusa to its board of directors, along with two additions to its executive leadership team.

"I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time," Ragusa said in the statement.

Alamar also named John Brottem as general counsel. Brottem previously served as general

Alamar Biosciences adds former Grail CEO to board, expands team

Mon, 05 Oct 2026 16:05:24 -0400

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced the appointment of Bob Ragusa to its board of directors, along with two additions to its executive leadership team.

"I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time," Ragusa said in the statement.

Alamar also named John Brottem as general counsel. Brottem previously served as general

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

Mon, 05 Oct 2026 16:05:00 -0400

Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer

FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the appointment of Bob Ragusa to its board of directors. Mr. Ragusa brings more than two decades of leadership across genomics, diagnostics and biotech. Most recently, he served as CEO of GRAIL, the pioneering multi-cancer early detection company, and previously as chief operations officer of Illumina.

"I am thrilled

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

Mon, 05 Oct 2026 16:05:00 -0400

Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer

"I am thrilled

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Thu, 24 Sep 2026 18:51:00 -0400

FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab.

Led by investigators at Washington University School of Medicine

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Thu, 24 Sep 2026 18:51:00 -0400

Led by investigators at Washington University School of Medicine

TD Cowen Reiterates Buy Rating on Alamar Biosciences (ALMR)

Thu, 24 Sep 2026 05:43:25 -0400

TD Cowen analyst Dan Brennan reiterated a Buy rating and $34.00 price target on Alamar Biosciences (NASDAQ: ALMR).

The analyst comments "We hosted senior management (Yuling Luo, Founder and CEO and Justin McAnear, CFO) for a series of investor meetings in NYC. Management delivered a bullish view on their business outlook & NULISA's competitive positioning ~5 months into being a public company. Growth opportunities abound (new panels, new indications, Dx opportunity), and management is focused on investing for growth."

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click

Form 4 Alamar Biosciences, Inc. For: Sep 14 Filed by: Brottem John L.

Wed, 16 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260916/27070537.html

Form 3 Alamar Biosciences, Inc. For: Sep 14 Filed by: Brottem John L.

Wed, 16 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260916/27070520.html

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 01 Sep 2026 16:05:00 -0400

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Alamar Biosciences’ management is scheduled to participate in a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 01 Sep 2026 16:05:00 -0400

About Alamar Biosciences, Inc.

Form SCHEDULE 13G Alamar Biosciences, Inc. Filed by: Luo Yuling

Thu, 13 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26922624.html

Form SCHEDULE 13G Alamar Biosciences, Inc. Filed by: Qiming Corporate GP VI, Ltd.

Tue, 11 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260811/26906517.html

Alamar Biosciences (ALMR) PT Raised to $32 at Stifel

Tue, 11 Aug 2026 10:08:11 -0400

(Updated - August 11, 2026 10:08 AM EDT)

Stifel analyst Daniel Arias raised the price target on Alamar Biosciences (NASDAQ: ALMR) to $32.00 (from $28.00) while maintaining a Buy rating.

The analyst commented, "ALMR posted a 2Q beat vs. Street and initiated a first-time guide that puts FY26 revenues ($116-120M range) above consensus ($113M), as well. With this being management's first call (and with disclosures such as placement totals and pull-through rates set to be annually provided numbers), details and discussion points were somewhat limited - but the business appears to be tracking nicely. The sales funnel sounds strong, expanding consortium initiatives

Alamar Biosciences (ALMR) PT Raised to $32 at Stifel

Tue, 11 Aug 2026 10:08:11 -0400

(Updated - August 11, 2026 10:08 AM EDT)

Stifel analyst Daniel Arias raised the price target on Alamar Biosciences (NASDAQ: ALMR) to $32.00 (from $28.00) while maintaining a Buy rating.

Alamar Biosciences (ALMR) PT Raised to $35 at JPMorgan

Tue, 11 Aug 2026 08:43:37 -0400

JPMorgan analyst Casey Woodring raised the price target on Alamar Biosciences (NASDAQ: ALMR) to $35.00 (from $32.00) while maintaining a Overweight rating.

Form 10-Q Alamar Biosciences, Inc. For: Jun 30

Tue, 11 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26900630.html

Alamar Biosciences, Inc. (ALMR) Reports Q2 Loss of $0.22

Mon, 10 Aug 2026 17:15:09 -0400

Alamar Biosciences, Inc. (NASDAQ: ALMR) reported Q2 EPS of ($0.22). Revenue for the quarter came in at $29.4 million.

For earnings history and earnings-related data on Alamar Biosciences, Inc. (ALMR) click here.